by kshughes | Mar 3, 2016 | Boadicea, BRCAPRO, Claus, Guidelines, Tyrer Cuzick
NCCN guidelines recognize Tyrer Cuzick, Claus, BRCAPRO and Boadicea. Gail is not recognized as appropriate. National Comprehensive Cancer Network. Available The American Cancer Society (ACS) recognizes Tyrer Cuzick, Claus, and BRCAPRO. American Cancer Society in its...
by kshughes | Mar 3, 2016 | Boadicea, BRCAPRO, Claus, Guidelines, Tyrer Cuzick
Despite Gail being inadequate and not approved by either the National Comprehensive Cancer Network (NCCN) or the American Cancer Society (ACS) guidelines, some insurance companies do accept it. The right models are BRCAPRO, Tyrer Cuzick and Claus. Boadicea has...
by kshughes | Mar 3, 2016 | BRCAPRO, Claus, Gail, Genetic Testing, Guidelines, Lifetime Risk, MRI, Population Level Risk, Tyrer Cuzick
If you use Tyrer Cuzick7, about 15% will need an MRI. If you use Claus, about 0.9% will need an MRI. If you use BRCAPRO, about 0.5% will need an MRI. [ASCO_2014_NCCNB_BRCAPRO_TyrerCuzickRiskMutationsLifetimeRisk]
by kshughes | Mar 3, 2016 | Boadicea, BRCAPRO, Claus, Gail, Hughes RiskApps, Hughes RiskApps Express, Models, Myriad, Tyrer Cuzick
Models have been developed for various situations and models will not run if they were not designed for the situation presented by your patient. A listing of models that will display as N/A under different situations follows: Model Will NOT run and display ‘N/A’ if…...
